MXPA04004355A - Tratamiento de combinacion que comprende zd6474 y un taxano. - Google Patents
Tratamiento de combinacion que comprende zd6474 y un taxano.Info
- Publication number
- MXPA04004355A MXPA04004355A MXPA04004355A MXPA04004355A MXPA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A MX PA04004355 A MXPA04004355 A MX PA04004355A
- Authority
- MX
- Mexico
- Prior art keywords
- taxane
- human
- combination therapy
- antiangiogenic
- warm
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 6
- 238000002648 combination therapy Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a un metodo para la produccion de un efecto antiangiogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente tal como un humano, particularmente un metodo para el tratamiento de un cancer que involucra un tumor solido, que comprende la administracion de XD6474 combinado con un taxano; a una composicion farmaceutica que comprende ZD6474 y un taxano, a un producto de combinacion que comprende ZD6474 y un taxano para uso en un metodo de tratamiento de un cuerpo humano o animal por terapia; a un equipo que comprende ZD6474 y un taxano; al uso de ZD6474 y un taxano en la elaboracion de un medicamento par uso en la produccion de un efecto antiangiogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente tal como un humano, el cual opcionalmente es tratado con radiacion ionizante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126879.6A GB0126879D0 (en) | 2001-11-08 | 2001-11-08 | Combination therapy |
PCT/GB2002/005021 WO2003039551A1 (en) | 2001-11-08 | 2002-11-06 | Combination therapy comprising zd6474 and a taxane |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04004355A true MXPA04004355A (es) | 2004-08-11 |
Family
ID=9925430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04004355A MXPA04004355A (es) | 2001-11-08 | 2002-11-06 | Tratamiento de combinacion que comprende zd6474 y un taxano. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050043395A1 (es) |
EP (1) | EP1446124B1 (es) |
JP (1) | JP4694127B2 (es) |
KR (1) | KR100959607B1 (es) |
CN (1) | CN1298328C (es) |
AR (1) | AR037346A1 (es) |
AT (1) | ATE335488T1 (es) |
AU (1) | AU2002337382B2 (es) |
BR (1) | BR0213906A (es) |
CA (1) | CA2464758C (es) |
CY (1) | CY1106259T1 (es) |
DE (1) | DE60213845T2 (es) |
DK (1) | DK1446124T3 (es) |
ES (1) | ES2269769T3 (es) |
GB (1) | GB0126879D0 (es) |
HK (1) | HK1068546A1 (es) |
IL (2) | IL161744A0 (es) |
MX (1) | MXPA04004355A (es) |
NO (1) | NO328048B1 (es) |
NZ (1) | NZ532525A (es) |
PT (1) | PT1446124E (es) |
WO (1) | WO2003039551A1 (es) |
ZA (1) | ZA200403455B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7173038B1 (en) | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
AU779695B2 (en) * | 2000-04-07 | 2005-02-10 | Astrazeneca Ab | Quinazoline compounds |
CA2473572C (en) | 2002-02-01 | 2011-05-10 | Astrazeneca Ab | Quinazoline compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
KR101089462B1 (ko) | 2002-11-04 | 2011-12-07 | 아스트라제네카 아베 | Src 티로신 키나제 억제제로서의 퀴나졸린 유도체 |
SI1592423T1 (sl) * | 2003-02-13 | 2011-07-29 | Astrazeneca Ab | Kombinacijska terapija ZD6474 s 5-FU in/ali CPT-11 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
WO2005049030A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
JP2008504292A (ja) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 免疫増強用の化合物 |
AU2005288737B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Combination comprising ZD6474 and imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
AU2009247782C1 (en) * | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
WO2010061208A2 (en) * | 2008-11-03 | 2010-06-03 | Astrazeneca Ab | Therapeutic treatment 555 |
CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
CN106478598B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种凡德他尼水合物晶体及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
JP2000510460A (ja) * | 1996-04-26 | 2000-08-15 | マゲイニン・ファーマシューティカルズ・インコーポレーテッド | スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療 |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
US6191290B1 (en) * | 1999-02-24 | 2001-02-20 | Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
CA2372053C (en) * | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US7173038B1 (en) * | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1534287A1 (en) * | 2002-08-09 | 2005-06-01 | Astrazeneca AB | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
SI1592423T1 (sl) * | 2003-02-13 | 2011-07-29 | Astrazeneca Ab | Kombinacijska terapija ZD6474 s 5-FU in/ali CPT-11 |
EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
AU2005288737B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Combination comprising ZD6474 and imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
-
2001
- 2001-11-08 GB GBGB0126879.6A patent/GB0126879D0/en not_active Ceased
-
2002
- 2002-11-06 CN CNB028267958A patent/CN1298328C/zh not_active Expired - Fee Related
- 2002-11-06 EP EP02772624A patent/EP1446124B1/en not_active Expired - Lifetime
- 2002-11-06 NZ NZ532525A patent/NZ532525A/en not_active IP Right Cessation
- 2002-11-06 BR BR0213906-5A patent/BR0213906A/pt not_active IP Right Cessation
- 2002-11-06 JP JP2003541842A patent/JP4694127B2/ja not_active Expired - Fee Related
- 2002-11-06 IL IL16174402A patent/IL161744A0/xx unknown
- 2002-11-06 PT PT02772624T patent/PT1446124E/pt unknown
- 2002-11-06 US US10/494,704 patent/US20050043395A1/en not_active Abandoned
- 2002-11-06 MX MXPA04004355A patent/MXPA04004355A/es active IP Right Grant
- 2002-11-06 CA CA2464758A patent/CA2464758C/en not_active Expired - Fee Related
- 2002-11-06 ES ES02772624T patent/ES2269769T3/es not_active Expired - Lifetime
- 2002-11-06 KR KR1020047007020A patent/KR100959607B1/ko not_active IP Right Cessation
- 2002-11-06 WO PCT/GB2002/005021 patent/WO2003039551A1/en active IP Right Grant
- 2002-11-06 AT AT02772624T patent/ATE335488T1/de active
- 2002-11-06 DK DK02772624T patent/DK1446124T3/da active
- 2002-11-06 AU AU2002337382A patent/AU2002337382B2/en not_active Ceased
- 2002-11-06 DE DE60213845T patent/DE60213845T2/de not_active Expired - Lifetime
- 2002-11-08 AR ARP020104292A patent/AR037346A1/es not_active Application Discontinuation
-
2004
- 2004-05-03 IL IL161744A patent/IL161744A/en not_active IP Right Cessation
- 2004-05-06 ZA ZA200403455A patent/ZA200403455B/en unknown
- 2004-06-07 NO NO20042365A patent/NO328048B1/no not_active IP Right Cessation
-
2005
- 2005-02-03 HK HK05100883A patent/HK1068546A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 CY CY20061101619T patent/CY1106259T1/el unknown
-
2011
- 2011-11-07 US US13/290,730 patent/US20120252827A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2464758C (en) | 2010-09-28 |
AU2002337382B2 (en) | 2008-06-12 |
JP4694127B2 (ja) | 2011-06-08 |
GB0126879D0 (en) | 2002-01-02 |
BR0213906A (pt) | 2004-08-31 |
EP1446124B1 (en) | 2006-08-09 |
IL161744A0 (en) | 2005-11-20 |
WO2003039551A1 (en) | 2003-05-15 |
CN1298328C (zh) | 2007-02-07 |
ATE335488T1 (de) | 2006-09-15 |
CY1106259T1 (el) | 2011-06-08 |
KR20050043779A (ko) | 2005-05-11 |
NZ532525A (en) | 2006-11-30 |
NO328048B1 (no) | 2009-11-16 |
KR100959607B1 (ko) | 2010-05-27 |
EP1446124A1 (en) | 2004-08-18 |
US20050043395A1 (en) | 2005-02-24 |
DE60213845T2 (de) | 2007-03-29 |
NO20042365L (no) | 2004-06-07 |
AR037346A1 (es) | 2004-11-03 |
DK1446124T3 (da) | 2006-11-13 |
ZA200403455B (en) | 2005-08-29 |
US20120252827A1 (en) | 2012-10-04 |
HK1068546A1 (en) | 2005-04-29 |
DE60213845D1 (de) | 2006-09-21 |
JP2005511597A (ja) | 2005-04-28 |
CN1612738A (zh) | 2005-05-04 |
PT1446124E (pt) | 2006-12-29 |
CA2464758A1 (en) | 2003-05-15 |
ES2269769T3 (es) | 2007-04-01 |
IL161744A (en) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0223380D0 (en) | Combination therapy | |
MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
ZA200600188B (en) | Combination therapy | |
IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
GB0223379D0 (en) | Combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |